Trading name Sinopharm Headquarters Beijing, China Founded 1998 Total assets 199.2 billion CNY (2014) | Type state-owned enterprise Revenue 247.1 billion CNY (2014) Net income 2.705 billion CNY (2014) | |
 | ||
Area served China, exported worldwide Key people Guo Jianxin (Chairman & Party Committee Secretary) Operating income Profit CN¥2.705 billion (2014) Parent organization State-owned Assets Supervision and Administration Commission of the State Council Subsidiaries Tianjin Guoda Pharmacy Chain Store Co., Ltd | ||
China National Pharmaceutical Group Corp. (CNPGC) known as Sinopharm is a Chinese state-owned enterprise. The corporation was the indirect major shareholder of publicly traded companies Sinopharm Group (SEHK: 01099, via a 51–49 joint venture, Sinopharm Industrial Investment, with Fosun Pharmaceutical), China Traditional Chinese Medicine (SEHK: 00570, mostly via Sinopharm Group Hongkong Co., Ltd.). Shanghai Shyndec Pharmaceutical (SSE: 600420, via a wholly owned research institute based in Shanghai) and Beijing Tiantan Biological Products (SSE: 600161, via China National Biotec Group).
China National Pharmaceutical Group was supervised by the State-owned Assets Supervision and Administration Commission of the State Council.
Several Sinopharm's subsidiary, such as China Sinopharm International Corp. and China National Pharmaceutical Foreign Trade Corp. were remained unlisted, which was not injected to Sinopharm Group.
Sinopharm was ranked 205th in 2016 Fortune Global 500 list.
History
China National Pharmaceutical Group Corporation (Chinese: 中国医药集团总公司) was founded in 1998 as a holding company for China National Pharmaceutical Corporation (Chinese: 中国医药(集团)公司), China National Pharmaceutical Industry Corporation (Chinese: 中国医药工业公司), China National Pharmaceutical Foreign Trade Corp. (Chinese: 中国医药对外贸易公司) and China National Medical Device (Chinese: 中国医疗器械工业公司). In 2009 it was merged with China National Biotec Group (Chinese: 中国生物技术集团公司).